Abstract

BackgroundSerum matrix metalloproteinase-3 (MMP-3) is a specific inflammatory marker of the synovium in patients with rheumatoid arthritis (RA).ObjectivesOur aim in this study is to investigate whether serum MMP-3 is the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0287 High Rate of Improvement in Serum Matrix Metalloproteinase-3 Levels at 4 Weeks PREDICT Remission at 52 Weeks in RA Patients with Anti-TNF Therapy
D Kida ... T Sato
Annals of the Rheumatic Diseases | VOL. 73
D Kida, et. al.D Kida ... T Sato
01 Jun 2014
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab
Takeshi Oguchi ... Hiroyuki Miyake
Modern Rheumatology | VOL. 28
Takeshi Oguchi, et. al.Takeshi Oguchi ... Hiroyuki Miyake
02 May 2017
Increased serum levels of cyclophilin a and matrix metalloproteinase-9 are associated with cognitive impairment in patients with obstructive sleep apnea
Zhangyong Xia ... Jinbiao Zhang
Sleep Medicine | VOL. 93
Zhangyong Xia, et. al.Zhangyong Xia ... Jinbiao Zhang
21 Oct 2021
Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus
...
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences | VOL. 33
, et. al. ...
01 Jul 2004
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers